Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27


Insulitis in human type 1 diabetes: The quest for an elusive lesion.

In't Veld P.

Islets. 2011 Jul-Aug;3(4):131-8. Review.


Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.

Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T.

Diabetes Care. 2009 Jul;32(7):1244-9. doi: 10.2337/dc09-0054.


Translating molecular insights in autoimmunity into effective therapy.

Feldmann M.

Annu Rev Immunol. 2009;27:1-27. doi: 10.1146/annurev-immunol-082708-100732.


Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.

Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss H Jr, Flier JS, Strom TB.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16242-7. doi: 10.1073/pnas.0808031105.


Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism.

Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13644-9. doi: 10.1073/pnas.0803429105.


Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts.

Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, Degauque N, Shi H, Fan Z, Flier JS, Auchincloss H Jr, Zheng XX, Strom TB.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13074-9.


Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice.

Tarbell KV, Petit L, Zuo X, Toy P, Luo X, Mqadmi A, Yang H, Suthanthiran M, Mojsov S, Steinman RM.

J Exp Med. 2007 Jan 22;204(1):191-201.


RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis.

Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J.

Bioinformatics. 2006 Nov 15;22(22):2825-7.


Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes.

Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien YH.

Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12475-80. Erratum in: Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15273.


Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M.

J Clin Invest. 2006 May;116(5):1371-81.


Gene signatures of progression and metastasis in renal cell cancer.

Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA.

Clin Cancer Res. 2005 Aug 15;11(16):5730-9.


A comprehensive review of interventions in the NOD mouse and implications for translation.

Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT.

Immunity. 2005 Aug;23(2):115-26. Review.


Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis.

Wilson CL, Miller CJ.

Bioinformatics. 2005 Sep 15;21(18):3683-5.


Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L.

N Engl J Med. 2005 Jun 23;352(25):2598-608.


The NOD mouse: a model of immune dysregulation.

Anderson MS, Bluestone JA.

Annu Rev Immunol. 2005;23:447-85. Review.


Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

Ogawa N, List JF, Habener JF, Maki T.

Diabetes. 2004 Jul;53(7):1700-5.


Islet regeneration during the reversal of autoimmune diabetes in NOD mice.

Kodama S, Kühtreiber W, Fujimura S, Dale EA, Faustman DL.

Science. 2003 Nov 14;302(5648):1223-7.


TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L.

Nat Med. 2003 Sep;9(9):1202-8.


Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA.

N Engl J Med. 2002 May 30;346(22):1692-8.

Items per page

Supplemental Content

Support Center